Allergic Contact Dermatitis
Conditions
Keywords
Allergic contact dermatitis, para-phenylenediamine, effector cells, regulatory cells, pathophysiology
Brief summary
The current knowledge of the pathophysiology of allergic contact dermatitis is based on the murine model. In this model, CD8+ T cells are effector cells, and CD4+ T cells regulate the response by limiting the expansion of CD8+ T cells. The goal of this study is to characterize the pathophysiology of contact dermatitis, with patients allergic to para-phenylenediamine (PPD). We suppose that the CD8+ T cells are the effectors of the allergic contact dermatitis, although the regulator cells belong to the LT CD4+ population. We will test our hypothesis on blood samples, and cutaneous biopsies of patients allergic to PPD.
Interventions
None listed
Sponsors
Hospices Civils de Lyon
Study design
Observational model
DEFINED_POPULATION
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
For both groups: * Patients aged from 18 to 65 years old. * Both genders eligible for study. * Female participants must use a contraceptive method. * Feasibility of patch testing. * Participants must be able to understand and sign the Informed Consent, and comply with all aspects of the protocol. * Patients must be registered in a social security system or with a health insurance coverage First group: allergic patients * Patients with allergic contact dermatitis to para-phenylenediamine (PPD) based on a history of PPD contact dermatitis and positive PPD patch tests. Second group : healthy volunteers * No history of PPD allergic contact dermatitis, with a negative PPD patch test.
Exclusion criteria
* Pregnant or lactating women. * Evolutive skin disease on the testing zone (lower back). * Patients with a clinically significant disease (chronic, recurrent or active). * Systemic corticotherapy or immunosuppressive treatment during the previous month, or local corticoid treatment the week before the patch testing. * Local or systemic drug use which interacts with the outcome measures. * Exposure to sun or UV radiations, 15 days before the patch testing. * Patients deprived of their civic rights, in custody, or subject to a tutorial, judiciary or administrative decision. * Patients subject to a protection measure. * Patients in a critical medical situation. * Patients with a personal situation judged by the investigator as unlikely to be compatible with optimal participation in the study, or which could constitute a risk for the patient. * Linguistic barrier or psychological profile preventing the patient from signing the consent form. * Patient still in an exclusion period following the participation in another clinical trial. * Patients having earned more than 4500€ in indemnities for participation in clinical trials during the previous 12 months, including this study.
Countries
France
Contacts
Primary ContactMarc Vocanson, PhD
Outcome results
None listed